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Half of the patients respond to the
experimental therapy; long-term data needed.

Retinoic acid/interferon combination
shows promising response rates
If found early enough, squamous cell carcinoma

Treatment Update

Scott M. Lippman is
an assistant professor
of medicine in the
Department of
Medical Oncology

(SCC) of the skin is curable: in the United States, over
90% of these cancers are successfully treated with surgeiy. Nevertheless, about 3,000 people die each year
from the disease. Their cancers are too far advanced to
attempt surgeiy or have metastasized to regional or
distant sites. No effective treatment exists for these
patients, according to Scott M. Lippman, M.D., assistant professor of medicine in the Section of Head,
Neck, and Thoracic Medical Oncology of the Department of Medical Oncology at The University
of Texas M. D. Anderson Cancer Center.
Lippman recalled his frustrating experience as a fellow
treating a patient with this advanced cancer. (Most
patients with this cancer see head and neck specialists,
because about 70% to 80% of secs of the skin are
located in the head and neck region. ) Because surgical
treatment is so effective for most patients, said Lippman,
''very advanced disease is rare, and there was no mention
of it in any of the textbooks of dermatology or medical
oncology. There was not even a sentence about systemic therapy (i.e., chemotherapy). As a medical
oncologist, I knew systemic therapy was necessary for
this patient, but there was nothing to guide me on what
regimen to use. I went through the literature and found
a few case reports here and there but no real series."
Lippman was thus inspired to address this problem in
his research, and now this work has identified a promising start to a new therapeutic regimen not only for sec
of the skin but also for SCC of the uterine cervix.
As a fellow, Lippman had become interested in
treating human cancers with retinoids, the natural and
synthetic analogues of vitamin A, which contribute to
normal development and differentiation of epithelial
tissues. Retinoids have long been studied for their
effects on cancer and are known to regulate malignant
cell differentiation and proliferation. Lippman and his
colleagues designed several limited studies that treated
sec ofthe skin with various retinoids, including 13-cis-

retinoic acid (13-cRA) (commonly known by one ofits
trade names, Accutane ). He also became aware ofa few
similarly small anecdotal studies in which patients with
SCC of the skin were treated with interferon-alpha 2a,
or Roferon-A, whose principal clinical uses today are
treating haiiy cell leukemia and AIDS-related Kaposi's
sarcoma. He was intrigued by the possibility that this
serious disease could be treated with a so-called biological systemic therapy, that is, one without the extreme
side effects of the cytotoxic chemotherapies. Even
though these studies were small (most included only six
or fewer patients), they were persuasive: 40% to 50% of
the subjects responded to the treatments.
Lippman had another reason for taking notice of the
therapeutic activity of the retinoids and interferon: he
and his collaborators on a team headed by Waun Ki
Hong, M.D., chief of the Section ofHead, Neck, and
Thoracic Medical Oncology, had shown that these
agents also are active in head and neck cancer
chemoprevention. (Hong is principal investigator of a
large multi.project program grant from the National
Cancer Institute to study chemoprevention of upper
aerodigestive tract cancers. ) In separate studies, both
13-cRA and interferon-alpha were somewhat effective
in reversing premalignant conditions of the skin.

Retinoid/interferon regimen conceived
From this evidence, Lippman and Hong devised a
regimen combining the two agents in advanced SCC of
the skin. Laboratory studies had shown that interferon
and 13-cRA have different mechanisms of action, act
synergistically, and have nonoverlapping and reversible
toxic effects; suggesting that any adverse effects caused
by the combination would be tolerable and reversible.
The retinoid's principal side effects are drying ofthe skin
and mucous membranes; interferon-alpha's side effects
include fatigue and a flu-like syndrome.
The first phase II clinical trial of the 13-cRA/interferon-alpha combination regimen at M. D. Anderson
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"The researchers knew ... that
a totally new approach was
needed"
•
Cancer Center was completed in 1991. Of the 28
evaluable patients with advanced SCC of the skin, 12
had partial responses and seven had complete responses,
a very encouraging 98% overall response rate. None of
the patients had life-threatening toxic effects, although
18 required dose reductions to relieve intolerable side
effects. As expected, all of these effects were reversible.
The favorable response rates and potential for relatively safe nonsurgical tumor destruction led Lippman,
Hong, and Irwin H. Krakoff, M.D., chairman of the
Department ofMedical Oncology, to plan further trials
in other advanced SCCs, particularly those ofthe cervix,
lung, and head and neck. Preliminary results have just
recently become available for the cervical cancer study.

Cervical cancers respond to regimen
The trial in advanced cervical carcinoma was conducted in Mexico, under Krakoff's direction, in collaboration with Mario Paredes-Espinoza, M.D ., of the
Department of Medicine of the Hospital Civil de
Guadalajara and the Instituto Jalisciense de
Cancerologia. Because regular screening for cervical
cancer is not as widespread in Mexico and other developing countries as it is in the United States, cervical
cancer is one of the major cancer killers in these countries. (In its advanced stages, it is relatively rare in the
U.S.) The disease usually goes undetected until the
tumor becomes apparent by its great bulk; the standard
treatment, radiotherapy, induces responses in about
40% of advanced cases, but the treatment is rarely
successful in achieving remission or prolonging survival.
Cytotoxic chemotherapy regimens have also been tried,
both alone and combined with radiotherapy, but have
not been able to improve on radiotherapy's survival rate.
Seeking to improve the standard treatment, Lippman
and his group turned to the 13-cRA/interferon-alpha
combination. Up.like carcinomas of the skin, however,
there was very little evidence that either agent was
effective in advanced cervical carcinoma. It was widely
accepted that biological therapies were effective only
against preinvasive or premalignant disease and small
and well-differentiated tumors, not bulky tumors like
advanced cervical carcinoma. The researchers knew,
however, that a totally new approach was needed, and
they believed that this regimen could induce responses
in cervical carcinoma as it had in skin carcinoma.
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•
Their study was the first known trial of this combination in cervical carcinoma. The researchers had hoped
for a 20% total response rate, but the results far exceeded
that goal: half (16) of the patients had at least a 50%
reduction in tumor size (including four patients who
had a complete remission). These results are provocative because they hint at the regimen's potential in this
prevalent and deadly disease.
Laboratory efforts are now directed at discovering
the mechanism for the regimen's effectiveness in skin
and cervical cancers. The researchers also want to determine which types and locations of cancer can be most
effectively treated with this regimen.
Lippman and his collaborators are looking to build
on their discovery to design a more effective therapy
for cervical cancer and, perhaps, for other advanced
SCCs. To this end, another study of cervical cancer is
already underway. John J. Kavanagh) :,.,1.D ., chiefofthe
Section of Gynecologic Medical Oncology at M. D.
Anderson, a key member of the cervical cancer study
team, said, "The first study showed that the 13cRA/interferon-alpha regimen has significam -linical activity in cervical cancer. We doubt that the
regimen alone will be effective enough to replace
radiotherapy as the standard therapy, however . Combined treatment modalities are the next step." In
the new study, the regimen is being used concomitantly with radiotherapy, and researchers have already learned that it sensitizes patients to the radiotherapy, making them more susceptible to both its
therapeutic and side effects. Lippman said, "This
regimen is so attractive because it has major activity,
just like the cytotoxic combinations. But, unlike
most cytotoxics, it can be given during radiotherapy
without destroying bone marrow, enhancing and
intensifying the effects without causing dangerous
side effects. The next study will sequentially combine these two therapies with cytotoxic therapy. For
these serious advanced cancers, such intensive and
condensed therapy is where we want to go." ■
Physicians who desire additional information may
write Scott M. Lippman, M.D., Department of Medical
Oncology, Box 80, The University of Texas M. D.
Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, or call (713) 792-6363.
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INTERVIEW

Silicone gel-filled implants: Women
should have the option to choose
IN APRIL, THE FooD AND DRUG ADMINISTRATION (FDA) MANDATED THAT SILICONE GELFILLED BREAST IMPLANTS BE STUDIED IN CONTROLLED CLINICAL TRIALS, LIMITING THE DEVICES' USE
PRIMARILY TO BREAST RECONSTRUCTION AFTER MASTECTOMY. TESTIFYING BEFORE AN
PANEL IN NOVEMBER OF

1991

FDA

ADVISORY

AND IN FEBRUARY OF THIS YEAR, OPPONENTS HAD CLAIMED THE

IMPLANTS CAUSED AUTOIMMUNE DISORDERS. MANUFACTURERS AND MANY PHYSICIANS CONTENDED,
HOWEVER, THAT SINCE TWO MILLION WOMEN HAVE THE IMPLANTS, IT IS A STATISTICAL CERTAINTY
THAT A SMALL PERCENTAGE OF WOMEN WOULD, COINCIDENTALLY, ALSO HAVE OTHER, UNRELATED
DISORDERS SUCH AS AUTOIMMUNE DISEASE. ALTHOUGH SUCH DISORDERS MAY INDEED BE
COINCIDENTAL, FDA COMMISSIONER DR. DAVID KESSLER STATED THAT THE "BURDEN OF
PROOF IS AN AFFIRMATIVE ONE, AND IT RESTS WITH THE MANUFACTURER."

0NCOLOGJS

MANAGING EDITOR INTERVIEWED THREE M. D. ANDERSON SURGEONS ABOUT THE FDA
DECISION: MARK A. SCHUSTERMAN, M.D.,
Ross,

M.D.

SCHUSTERMAN,

S.

EVA SINGLETARY, M.D., AND MERRICK

I.

A PLASTIC RECONSTRUCTIVE SURGEON, WAS A MEMBER OF A

MULTISPEC IALTY GROUP THAT ADVISED THE

FDA.

SINGLETARY, A SURGICAL ONCOLOGIST,

TREATS BREAST CANCER PATIENTS, AND Ross, ALSO A SURGICAL ONCOLOGIST WHO TREATS
BREAST CANCER PATIENTS, TESTIFIED AT THE

-----

•-----

Mark A. Schusterman, M.D.

Q
What was your reaction to Kessler's statement?
How do you think it addressed the problem?
A
Our feeling was fairly neutral about that. We've
always kept our implant patients on a registry, so the
ruling is not going to affect us, except in making a
bit more paperwork that the FDA has mandated.
We've always maintained that synthetic, implanted
devices need to be tracked long term. For the most
part, we feel that these devices are extremely safe,
but any medical therapy has a calculated risk. Giving
penicillin has a risk. Giving aspirin has a risk. These
devices have a risk, too. The question is, what is the
benefit compared with that risk? For mastectomy
patients, there's no question in my mind that the
benefit far outweighs any element of risk. In our
registry of [ silicone gel-filled implant] patients, we
have over 300 patients whom we've followed for
about six years, and none of these patients have had
a serious problem: no implant ruptures, no serious
infections. We have had some minor infections and
implant losses but nothing unusual. One implant
patient did have a so-called autoimmune disease,
but it was very mild, was treated with steroids, and

FDA

HEARINGS IN WASHINGTON,

D.C.

resolved. A patient in another group had a similar
syndrome, but did not have an implant. Was the one
case of autoimmune disorder a background occurrence, or was there a cause-and-effect relationship?
There doesn't seem to be a cause-and-effect relationship, but again, we're always concerned about
any device that is implanted in someone's body, so
we continue to follow these patients. The FDA
mandate is welcomed. It's just good patient care.

Commentary

Q
Are you familiar with Dr. Bernard Patten from
Baylor College of Medicine (Houston)? The
press has reported that 111 women who have
had breast implants are being treated by Dr.
Patten for some type of autoimmune problem.
What is your assessment?

Mark A. Schusterman,
an assistant professor of
plastic and reconstructive
surgery, is deputy chairman
of the Department of
Plastic and Reconstructive
Surgery

A
Dr. Patten makes his diagnosis fairly liberally, and his
criteria are simply any type of unusual complaint: fatigue,
headaches, for example. It's very difficult for me to see
how he can draw a cause-and-effect relationship with that
kind ofsymptomatology. Current laboratory tests are very
nonspecific. Some of the autoimmune tests can become
weakly positive under a variety of circumstances, and the
real hard evidence showing cause and effect is simply not
there. We have followed our own series of patients very
carefully, and we just haven't seen the same thing.

page 3

MD Anderson Oncolog

'-To deny women [the] option of
silicone implants because of this media blitz seemed unfair"
•
Q

----•----

Are there any other such data bases as yours, and
what role did it play in the FDA's decision?

s. Eva Singletary, M.D.

A
I think its role was significant. It's the only data that we
know of, the only prospective study with a significant
number of patients in it. We're hoping to publish the
data soon. It's important for this information to be in
the medical literature.

What do you tell a patient about the risks of
silicone implants?

Q
Commentary

Q
In the mid- l 970s, regulations changed the way
new devices were studied, but because the implants
were already on the market, they were exempted
from the new regulations. What at that time were
the known risks of silicone?
S. Eva Singletary is an
assistant professor
of surgery in the
Department of
General Surgery

A
Silicone was thought to be an inert biomedical substance. It was-and still is-widely used throughout
the biomedical industry as an implantable substance. It's
currently used in heart valves and all types of medical
devices, not just plastic surgery devices. One of the
fallouts from the implant controversy is that if silicone becomes a health hazard because of"political"
controversy rather than scientific data, it's going to
affect all of health care. Arthritis patients, heart valve
patients, and all types of patients getting prosthetic
joints will be affected [since silicone is used in
devices designed for these patients].·I think we need
to be very careful; before we start saying something
is dangerous, we should get the information in.

Q
What was your feeling when Kessler made the
annonncement in April? Were you relieved?
A
Yes. Overall, plastic surgeons may have felt it was a
defeat, because the majority of implants are used for
aesthetic augmentation, but from the reconstructive
surgeon's viewpoint, it was a victory. We felt that
our job in being able to enhance the quality of life
for breast cancer patients was going to be preserved,
and that gave us a sense of relief.
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A
I begin by going through all the different types of
reconstruction. In describing silicone implants in particular, I tell her that we don't know the actual risk
associated with silicone and that we don't know the
frequency of autoimmune problems, either immediate
or long-term. That's definitely a concern. Seeing no
autoimmune disorders in five years doesn't mean we
won't see them 25 years. Women with implants simply
haven't been followed for that length of time. Most
patients, though, even after you explain what we know
and don't know, are still willing to take that risk. Other
women, however, as a consequence of all the media
coverage, don't even want to discuss implants. For
them we look at the option of tissue flap reconstruction. And still other women simply don't want to
hear about any type of reconstruction. T hey've been
barraged with media reports and are very frightened .
A diagnosis of breast cancer is very distressing.
When you add to that the controversy over implants, the situation becomes even more emotional,
making it hard for patients to make a decision.

Q
Even a decision about reconstruction which
doesn't use silicone?
A
Right. Some patients, once they hear the term "reconstruction," don't even want to consider it. We tell them
about alternatives such as saline implants and tissue flap
reconstruction-we prefer the tissue flap reconstruction, but some women aren't candidates for that. That's
why Drs. Schusterman and Ross got involved in the
FDA hearing, because to deny women that option of
silicone implants because of this media blitz seemed
unfair. It seemed much more logical to let the patient
make a choice.
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"Implants can be very important to
many patients in terms of overall
well-being and self-image"
•
Q
What is the typical reaction of patients who have
heard the reports but still want a silicone implant?
Do they just say, "It's important to me from an
emotional standpoint, and I'll assume the risk?"

A
Yes. They've more or less made up their mind how
they feel about implants before we even begin the
discussion. Either they're for it or they're totally dead
set against it. Nowadays breast cancer patients are very
educated. Once they get the diagnosis they get their
hands on all the information, so they've pretty much
read all the reports about the implants.

Q
How long do you think it will take for the controlled clinical trials recently mandated by the FDA
to come up with some meaningful data?

Q
Is there anything else you'd like to add?

A
Informed choice is the most critical issue. How this was
handledfii.ghtened women unnecessarily. Women could
react more appropriately ifthey received balanced information rather than anecdotal accounts. That was just
sensationalism. The situation concerned us because
sensationalized accounts may have scared women from
getting mammograms. We were afraid that women
would say, "Ifl have breast cancer, and ifl have to have
a mastectomy, and if implants are dangerous, then I
don't have any options." And that may make women
reluctant to find out whether they have breast cancer.

---•---

Merrick I. Ross, M.D.

Commentary

Q
A
One would have to look at the probability that there is
a significant risk, because if the risk is very small, we
won't find the answer until we're doing the procedure
in very large numbers, with follow-up of 10 years or
more. And that may be the case. Based on our
computerized registry, we haven't seen a problem.
It's important to do these studies, but we're not
going to have the answer anytime soon.

Q
Do you think the registry played a significant
role in the FDA's decision?
A
I think it did. Most of the testimony had been
emotional appeals both by patients and by physicians, and no one had any hard data. I think that our
data were very important in arguing for implants as
rehabilitation. If implants are to be restricted, they
should be restricted for cosmetic reasons. We don't
consider breast reconstruction after mastectomy as
cosmetic; it's part of rehabilitation. I think its being
presented in that way was a major factor in lifting the
moratorium.

What was your reaction to the April FDA ruling,
which mandated that implants could only be
used in controlled clinical trials? Do you think it
was good, bad, warranted?
A
The ruling is warranted and makes good sense. It's
sound medical practice to obtain prospective information about any medical device or drug so that the true
character and incidence of side effects can be determined. Unfortunately, anecdotal events concerning
less-than-desired outcomes after placement of implants
or isolated, serious side effects have been sensationalized
in the press. The reports have been fairly one sided; we
[at M. D. Anderson, on the other hand] follow a large
number of patients who are thrilled at how helpful the
implants have been to their cancer rehabilitation. The
implants can be very important to many patients in
terms of overall well-being and self-image. We are
happy that we can continue to provide this important service to our breast cancer patients.

Merrick I. Ross, an assistant
professor of surgery, is chief
of the Melanoma Section
in the Department of
General Surgery

Q
You implied that the media coverage has been
bad from the standpoint of emphasizing anecdotal
continued on page 7
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Cross-matching
continued from page 8
to make one unit ofrandom-donor platelets, the patient

will likely be exposed to four to six different sets of
platelet antigens (from each of the individuals who
donated a unit of whole blood). For each episode of
thrombocytopenia-and there may be several over the
course of a protocol-the patient may require numerous units of platelets and thus be subjected to what
Ogden calls intense "antigenic stimulation." The efficacy ofplatelet transfusion, however, depends on minimizing antibody production by minimizing the
patient's exposure to antigens. Platelet antigens vary
somewhat within the human population, but not to a
great extent. If a patient is rapidly exposed to all platelet
antigens normally found in the population, then
subsequent episodes of thrombocytopenia may be
untreatable, since preexisting antibodies will target
virtually any new platelets that are transfused.
Platelets from single donors are better
The rate of alloimmunization can, theoretically, be
slowed by using single-donor platelets, thus exposing
the patient to only one donor's antigens. By limiting
antigenic exposure, the clinician can increase the odds
that the platelets from future donors (who may have a
different set of antigens) will be compatible with the
patient. Although Ogden said that this approach is
preferable to random-donor platelets, it still leads to
alloimmunization, albeit more slowly. Furthermore,
there is no guarantee that the single-donor platelets will
help the patient. Generally, single-donor platelets are
not tested for compatibility before transfusion (an exception is human leukocyte antigen [HI.A] typing,
described below). The platelets' effectiveness is determined by monitoring platelet counts after transfusion.
Such delays clearly are not desirable when a patient is in
critical condition. An efficient and inexpensive test, like
cross-matching, that determines compatibility beforehand has clear, clinical benefits.
If donor-patient compatibility is determined before
transfusion, the long-term process of alloimmunization
can be further slowed, and, in the short term, the patient
is more likely to demonstrate a sustained platelet increment through each acute thrombocytopenic episode,
since the tested platelets have a high likelihood of being
effective. (The testis about 90% predictive.) In addition,
the M. D. Anderson test is more practical and less
expensive than another common assay, HI.A typing.
(Ogden pointed out that several other tests exist but
cannot be used because ofthe high expense or logistical
difficulty of performing them. To a lesser degree, these
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factors have also limited the application ofHIA typing.)
In terms of predicting compatibility, HI.A typing is
about 85% accurate. "The two tests are about the same
in accuracy," Ogden said. "But the cross-matching test
is easier to perform and less expensive. Also, other [nonHIA] platelet antigens that play a role in rejection are
detected by the cross-matching test, whereas HIA
typing detects only human leukocyte antigens." HI.A
typing costs about $300 per donor sample, whereas the
M. D. Anderson test costs about $15 per donor sample.
"That's what we were after," Ogden said. "A test that
could be used quickly and easily and with that kind of
success rate."
Long-term storage a major advantage
Unlike HI.A typing, which requires fresh donor
lymphocytes, the cross-matching test employs latex
beads as long-term storage vehicles for platelet antigens.
Samples used for cross-matching can be stored for up to
six months by immediately processing half the sample
into latex beads (which will maintain the antigens'
viability for three to four months) and by freezing the
other halffor future use. Although freezing destroys the
platelets' usefulness for transfusion, it preserves antigens,
thus maintaining the platelets' usefulness for the test.
Three months after the sample is taken, the frozen half
is thawed and processed into latex beads. With this
approach, a donor's sample could be cross-matched, as
needed, at any time during the six-month period.
Donors therefore need not be called in until their
samples have been tested and shown to be compatible.
Up to 250 donor samples per day can be screened with
the cross-matching test, whereas only about 20 HI.A
typings can be done per day. Ogden noted that "it is
not uncommon to find a patient that is compatible
with only one donor out of a 100." Thus the ability
to screen 250 donors per day greatly enhances the
chances that compatible donors can be identified
within 24 hours for most patients. However, Ogden
added that, in rare instances, compatible donors are
never found.
Banking the samples, though, is no easy task. About
15 samples can be processed and banked per day,
assuming, of course, that donors are available. Ogden
would like to recruit 500-1000 donors and bank their
samples. Doing so, Ogden believes, would meet the
platelet needs of the entire patient population at M . D .
Anderson, if donors would commit to three or four
donations a year. From a donor's perspective, this
would be an improvement, since some donors are
currently asked to donate much more frequently than
that. This is so because of the inefficiency of the current
method of using platelets that are not pre-tested for
compatibility; many units of platelets are ineffective,
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thus requiring additional transfusions. By ensuring
compatibility beforehand, however, fewer units-and
thus fewer donations per donor-will be needed.
Ogden would like to minimize the need for frequent
donations, since he realizes that donors are making a
tremendous sacrifice: the procedure takes about two
hours, not to mention travel time to and from M. D.
Anderson. The cross-matching test may indirectly
eliminate this problem. Because the test can quickly
identify multiple compatible donors, the burden of
donation for a particular patient can be spread across,
say, ten donors as opposed to one or two.
Mobile unit can now go to the donors
A new mobile platelet collection unit may also make
things easier for donors. ''We've always tried to accommodate our donors by keeping the transfusion clinic

open after hours and on weekends, but now with a
mobile unit we can go to directly to the donors," Ogden
said. ''We'd like to develop relationships with companies and institutions for periodic site visits."
With platelet cross-matching, Ogden hopes that donors will be asked to donate fewer times, while patients
still receive the benefit of a ready supply of compatible,
more effective platelets. With the mobile unit and sustained, traditional recruiting efforts, Ogden is confident
that this hope can be realized. ■
Physicians who desire additional information may write
Daryl Ogden or Benjamin Lichtiger, M.D., Ph.D., Transfusion Medicine and Laboratory Immunology, Box 007, The
University of Texas M. D. Anderson Cancer Center, 1515
Holcombe Boulevard, Houston, Texas 77030, or call (713)
792-2658.
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The University of Texas
M. D. Anderson Cancer Center
President,
Charles A. LeMaistre, M.D.

Breast Implants

ing mastectomies as an option?

continued from page 5
A
information. Could coverage have been improved?

A
The media could have interviewed patients who have
had no problems whatsoever and are very pleased
with the results. The vast majority of patients are very
satisfied with the outcome and convey how the implants have had a positive impact on their lives. A
balanced report would have been more responsible
journalism and more accurately reflected the situation.
The preponderance of anecdotal negative reports is
very misleading, suggesting that complications [capsular contracture, leakage, rupture, and autoimmune
disorders] are common when in fact they are rare.

Q
What would you say to a woman who has implants
and has heard all the news reports?

A
If anxiety over potential side effects is overwhelming
and adversely affecting her life-style, then she should
consider having the implants replaced [with saline implants] or removed. Such anxiety is a reasonable
enough impetus to warrant removal, purely for
emotional support. But from a medical standpoint,
no data link silicone implants to autoimmune disorders or other side effects mandating removal.

Q
Would a ban on implants indirectly affect choos-

A lot of fear is associated with mastectomy, particularly in the absence of a viable reconstructive option.
If patients feel they have no option, then denial of
disease may develop just to avoid mastectomy,
delaying the diagnosis. I'm also concerned that,
in the absence of good evidence that implants are
harmful, a strict ban infringes on a woman's right
to choose. Almost anything in medicine has some
side effects. That's why we have informed consents. Another potential concern is that a ban may
result in a broadening of the indications for breast
conservation surgery. We use breast-preserving
approaches ( a lumpectomy plus radiation therapy)
in treating breast cancer whenever possible, but
some patients are not appropriate candidates because of the location of the tumor, size of the
tumor, or the size of their breasts. If implants had
been banned, surgeons may have pushed the
limits of breast conservation surgery by extending
t e mdicat1ons JUSt to avmd a mastectomy. Such a
practice may not be oncologically safe, as it may
result in an increased recurrence incidence. This
could be a dangerous and realistic pitfall. ■
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Physicians who desire additional information may write
Drs. Schusterman, Ross, or Singletary at Boxes 62, 106,
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Anderson Cancer Center, Division of Surgery, 1515
Holcombe Boulevard, Houston, Texas 77030, or call
(713) 794-1247 (Schusterman), 792-7217 (Ross), or
792-6937 (Singletary).
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Cross-matching test helps find donors for
patients in dire need of platelets
Lab to Clinic

Daryl Ogden is supervisor
of the Histocompatibility
Testing Laboratory

A sneeze, a cough-these are minor irritations to
most of us, but not to patients who undergo aggressive chemotherapy. A potentially fatal side effect of
such therapy, thrombocytopenia, makes the usually
unnoticed, daily episodes of minor bleeding a cause
for alarm. "In healthy people, small capillaries are
breaking all the time, but hemostasis is maintained
by the clotting mechanism that involves plasma
protein and platelets. In thrombocytopenic patients
that's not the case. A simple cough or episode of
nausea, which can be severe with some aggressive
chemotherapies, can rupture capillaries. If the patient is thrombocytopenic, even such small ruptures
can lead to potentially fatal internal bleeding," said
Daryl Ogden, M.S., supervisor of the Histocompatibility Testing Laboratory in the Section ofTransfusion Medicine and Laboratory Immunology at The
University ofTexas M. D. Anderson Cancer Center.
The standard treatment for thrombocytopenia is
platelet transfusion, but such transfusions can be rendered ineffective if the patient has been alloimmunized,

a condition in which the patient develops antibodies
against all platelets. Because it is difficult to sustain
adequate levels of platelets in alloimmunized patients,
researchers have been attempting to develop strategies
that not only make transfusions more effective but also
slow the process of alloimmunization. Working with
Benjamin Llchtiger, M.D., Ph.D, and Ayman Asfour,
M.B.Ch.B, Ogden has developed a new platelet crossmatching test that provides at least one such strategy.
Alloimmunization is a manifestation of the nonnar-immune response. In regard to platelet transfusion,
however, instead ofattacking foreign substances that are
harmful, the immune system attacks those that are lifesaving. The immune system recognizes transfused platelets as foreign and eventually develops antibodies to
platelet antigens, molecules on the surface of platelets.
The antibodies recognize the platelet antigens and bind
to them, thus activating the immune system to destroy
the transfused platelets. Alloimmunization is especially
pronounced when random-donor platelets are used.
Given that four to six units of whole blood are required
continued on page 6

